Construction of an endoplasmic reticulum stress-related signature in lung adenocarcinoma by comprehensive bioinformatics analysis

Y Wang, J Nie, L Dai, W Hu, S Han, J Zhang… - BMC Pulmonary …, 2023 - Springer
Abstract Background Lung Adenocarcinoma (LUAD) is a major component of lung cancer.
Endoplasmic reticulum stress (ERS) has emerged as a new target for some tumor …

[HTML][HTML] Real-world prevalence of PD-L1 expression in non-small cell lung cancer: an Australia-wide multi-centre retrospective observational study

PA Russell, AL Farrall, S Prabhakaran, K Asadi… - Pathology, 2023 - Elsevier
An investigator-initiated, Australia-wide multi-centre retrospective observational study was
undertaken to investigate the real-world prevalence of programmed death ligand-1 (PD-L1) …

Clinical utility of rapid on-site evaluation of brush cytology during bronchoscopy using endobronchial ultrasound with a guide sheath

K Nishiyama, K Morikawa, S Kaneko, M Nishida… - Scientific Reports, 2024 - nature.com
Previous studies have shown that rapid on-site evaluation (ROSE) improves the diagnostic
yield of bronchoscopy using endobronchial ultrasound with a guide sheath (EBUS-GS) for …

[HTML][HTML] Development of Ex Vivo Analysis for Examining Cell Composition, Immunological Landscape, Tumor and Immune Related Markers in Non-Small-Cell Lung …

EG Ufimtseva, MS Gileva, RV Kostenko, VV Kozlov… - Cancers, 2024 - mdpi.com
Simple Summary Lung cancer, including non-small-cell lung cancer (NSCLC), is one of the
leading causes of cancer-related deaths worldwide. NSCLC treatment has undergone a …

The detection of PD‐L1 expression on liquid‐based cytology in pleural effusion of lung adenocarcinoma and its prognostic evaluation: Between paired liquid‐based …

H Ma, J Jia, Z Sun, X Xiao, S Liang… - Diagnostic …, 2024 - Wiley Online Library
Background Programmed death‐ligand 1 (PD‐L1) expression levels measured by
immunohistochemistry have been proven to predict the outcome of immunotherapy in lung …

Quantification de l'immunomarquage spécifique par nanoparticules plasmoniques sur lignées cellulaires cancéreuses

G Ortiz - 2022 - publications.polymtl.ca
Le cancer est une maladie extrêmement complexe et les traitements disponibles sont
multiples. L'un d'eux, l'immunothérapie, cible spécifiquement certaines protéines …